Recent Updates — BBIO
BridgeBio Pharma reported third-quarter net revenues of $353.2 million, driven by a $145 million year-over-year increase in Attruby product sales and a $75 million Bayer sales milestone. The company recorded a net loss attributable to common stockholders of $83.0 million, or $0.42 per share. To fund upcoming launches and operations, BridgeBio issued $632.5 million in principal amount of 1.95% senior notes due 2033. Cash, cash equivalents, and marketable securities totaled $1.5 billion as of September 30, 2026. The company operates as a commercial-stage biopharmaceutical firm developing medicines for genetic conditions.
The FDA has accepted BridgeBio Pharma's New Drug Application for oral infigratinib to treat children with achondroplasia and granted it Priority Review status. The agency assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 4, 2027. If approved, the drug would be the first and only approved oral therapy for this condition. BridgeBio plans to submit a Marketing Authorization Application to the European Medicines Agency in the fourth quarter of 2026. The company operates as a commercial-stage biopharmaceutical firm focused on developing medicines for genetic conditions.
On August 31, 2026, BridgeBio Pharma entered into a voluntary agreement with the U.S. government to expand Medicaid access for its medicine Attruby via the GENEROUS Model and lower drug costs for American patients. The company expects this arrangement to exclude future pricing mandates for medicines approved exclusively for orphan indications. Specific financial terms remain confidential. BridgeBio operates in the biopharmaceutical industry, developing and commercializing transformative medicines for rare genetic conditions.
BridgeBio Pharma, Inc. announced the pricing and launch of a secondary public offering of 5,000,000 shares of common stock by selling stockholder KKR Genetic Disorder L.P. The shares were priced at $78.00 per share, with an expected closing date of August 17, 2026. BridgeBio will not receive any proceeds from the sale and is not issuing new equity. The transaction aims to diversify the company's institutional shareholder base toward high-quality, long-term ownership. This filing discloses a material definitive agreement for the underwriting of these shares via William Blair & Company, Goldman Sachs & Co. LLC, and KKR Capital Markets LLC. BridgeBio Pharma operates in the biopharmaceutical industry, developing medicines for genetic conditions.
BridgeBio Pharma reported second quarter 2026 financial results showing total revenues of $243.7 million, driven by $222.4 million in U.S. Attruby net product revenue. The company closed a $1 billion preferred equity financing on July 1, 2026, and holds $720.2 million in cash as of June 30, 2026. Regulatory milestones include FDA acceptance with Priority Review for BBP-418 (PDUFA November 27, 2026), encaleret (PDUFA May 8, 2027), and the submission of an NDA for oral infigratinib. The company operates as a commercial-stage biopharmaceutical firm developing medicines for genetic conditions.
BridgeBio Pharma, Inc. announced that the FDA has accepted for filing its New Drug Application (NDA) for encaleret to treat autosomal dominant hypocalcemia type 1 (ADH1). The FDA has assigned a PDUFA target action date of May 8, 2027, and the company is preparing to launch the therapy upon approval. BridgeBio is also planning to submit a Marketing Authorization Application (MAA) to the EMA in the second half of 2026. BridgeBio Pharma, Inc. is a biopharmaceutical company focused on developing medicines for genetic conditions.